Genomic alterations in this tumour include amplification of the wild-type KRAS allele accompanied by increased levels of GTP-KRAS (M. Nokin et al., unpublished observations), which contributes to diminished response to sotorasib treatment at 50 mg kg−1 daily. Here, KRAS is linked to neoplasm.